Yahoo! Finance: Top Stories

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

May 30, 2025 - 13:46
 0
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold
Read More

Tags:

Previous Article

Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&...

Next Article

University Endowments Are Breaking Up With Private Equity. It’s Hard to Do.

Related Posts

China's Pony AI Robotaxi Revenue Jumps 200%, Eyes 1,000-Vehicle Fleet

China's Pony AI Robotaxi Revenue Jumps 200%, Eyes 1,000...

May 20, 2025  0

CoreWeave (CRWV) Stock Jumps 157%—But Analyst Warns the Rally Looks Risky

CoreWeave (CRWV) Stock Jumps 157%—But Analyst Warns the...

May 28, 2025  0

Meet Fidji Simo, the Instacart CEO Tasked With Getting OpenAI to Turn a Profit

Meet Fidji Simo, the Instacart CEO Tasked With Getting ...

May 21, 2025  0